Suresnes, September 4, 2023 – 8:00 p.m. CET – The Board of Directors of NEOVACS (Euronext Growth Paris: ALNEV), on the basis of the 8
th
resolution voted at the General Meeting of June 30, 2023, decided to carry out a capital reduction motivated by losses by reducing the par value of the Company’s share.
The par value of the share is reduced from 0.05 euro to 0.005 euro. The Company’s share capital, divided into 9,090,681 shares, has been reduced from 454,534.05 euros to 45,453.4050 euros.
ABOUT NEOVACS
Neovacs is a French biotechnology company, listed on Euronext Growth since 2010, specializing in therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology called Kinoid®, patented until 2038, makes it possible to induce a polyclonal immune response, applicable in several indications. Neovacs has developed IFNα Kinoid for the treatment of lupus in a phase IIb clinical study. The main study has been completed, the full results were presented on the 13
th
2019 international lupus congress. The Company has also completed promising preclinical work with another therapeutic vaccine, IL-4/IL-13 Kinoid, for the treatment of allergies. The ambition of this “Kinoid® approach” is to enable patients to better tolerate a lifelong treatment which would be more effective, well tolerated and very flexible in its administration.
For more information :
www.neovacs.fr
Jérôme FABREGUETTES-LEIB | Anne-Charlotte DUDICOURT |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
ypmalMacZJuYyGlvlstpaZeYmZiUxJbKmWKdlmFoa8yWnXJlyWqWmseVZnFim2Zp
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/81613-nvcs_cp_nominal_sept_2023_vdef.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com